Mangold GL - Search Results

1

Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.

Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK. Reddy KB, et al. Among authors: mangold gl. Cancer Res. 1992 Jul 1;52(13):3636-41. Cancer Res. 1992. PMID: 1617636

2

Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.

Wadkins RM, Potter PM, Vladu B, Marty J, Mangold G, Weitman S, Manikumar G, Wani MC, Wall ME, Von Hoff DD. Wadkins RM, et al. Cancer Res. 1999 Jul 15;59(14):3424-8. Cancer Res. 1999. PMID: 10416605

3

A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.

Raymond E, Sun D, Izbicka E, Mangold G, Silvas E, Windle B, Sharma S, Soda H, Laurence R, Davidson K, Von Hoff DD. Raymond E, et al. Br J Cancer. 1999 Jul;80(9):1332-41. doi: 10.1038/sj.bjc.6690526. Br J Cancer. 1999. PMID: 10424733 Free PMC article.

4

Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.

Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM. Morgan AS, et al. Cancer Res. 1998 Jun 15;58(12):2568-75. Cancer Res. 1998. PMID: 9635580

5

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Britten CD, et al. Cancer Res. 1999 Mar 1;59(5):1049-53. Cancer Res. 1999. PMID: 10070962

6

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A. Shimizu T, et al. Among authors: mangold gl. Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19. Clin Cancer Res. 2012. PMID: 22261800

7

Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.

Weitman S, Mangold G, Marty J, Dexter D, Hilsenbeck S, Rake J, Juniewicz P, Von Hoff D. Weitman S, et al. Cancer Chemother Pharmacol. 1999;43(5):402-8. doi: 10.1007/s002800050914. Cancer Chemother Pharmacol. 1999. PMID: 10100596

8

Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).

Hao D, Rizzo JD, Stringer S, Moore RV, Marty J, Dexter DL, Mangold GL, Camden JB, Von Hoff DD, Weitman SD. Hao D, et al. Among authors: mangold gl. Invest New Drugs. 2002 Aug;20(3):261-70. doi: 10.1023/a:1016253716438. Invest New Drugs. 2002. PMID: 12201489

9

Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.

Zeng Q, Kwok Y, Kerwin SM, Mangold G, Hurley LH. Zeng Q, et al. J Med Chem. 1998 Oct 22;41(22):4273-8. doi: 10.1021/jm980265c. J Med Chem. 1998. PMID: 9784102

10

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD. MacDonald JR, et al. Among authors: mangold gl. Cancer Res. 1997 Jan 15;57(2):279-83. Cancer Res. 1997. PMID: 9000568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters